Printer Friendly
The Free Library
18,914,768 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Endovasc Ltd., Inc. Clears Comments On Form 10 and is Now a Reporting Company.


Business Editors

MONTGOMERY Montgomery, city, United States
Montgomery, city (1990 pop. 187,106), state capital and seat of Montgomery co., E central Ala., near the head of navigation on the Alabama River just below the confluence of the Coosa and Tallapoosa rivers, and in the rich
, Texas--(BUSINESS WIRE)--April 19, 2000

Endovasc Ltd., Inc. (OTC OTC

See: Over-the-counter.


OTC

See over-the-counter market (OTC).
 BB:ENDV) announced today that its Form 10 has cleared comments with the Securities and Exchange Commission, and that as of today, the Company became a reporting company upon the effectiveness of its registration statement on Form 10-SB filed with the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area.  Securities and Exchange Commission for the registration of its common stock under Section 12(g) of the Securities Exchange Act of 1934.

Dr. David P. Summers, Chairman and Chief Executive Officer of the company commented, "This is an important step for the company and shareholders. With this milestone accomplished, the company can now concentrate on the closure of funding efforts and a return to the OTC Bulletin Board OTC Bulletin Board

An electronic quotation listing of the bid and asked prices of OTC stocks that do not meet the requirements to be listed on the NASDAQ stock-listing system.
."

Comments from Endovasc Vice President of Business Development, Roy A.

Robertson echoed Dr. Summers' remarks and added that, "There are many opportunities for growth in this industry for Endovasc, and now the company can move forward with the clinical trials protocols and further collaborations and alliances with companies and universities."

Endovasc Ltd., Inc. is a biopharmaceutical company using liposomal drug delivery for products that have already shown safety and efficacy in generic form. The company's products and processes are covered by patents and trade secrets for competing in a $2 billion market. In February of this year, the company obtained a world-wide exclusive license to the use of N-RAX from Stanford University Stanford University, at Stanford, Calif.; coeducational; chartered 1885, opened 1891 as Leland Stanford Junior Univ. (still the legal name). The original campus was designed by Frederick Law Olmsted. David Starr Jordan was its first president. .

The foregoing statements are made under the "Safe Harbor Safe Harbor

1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated.

2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive.
" statement under the Private Securities Legislation Reform Act of 1995. Any forward-looking statements forward-looking statement

A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections.
 contained herein are based on the company's historical performance. They are subject to various risks and uncertainties detailed from time to time in the company's filings with Securities and Exchange Commission and may not be evident at the time of this release.
COPYRIGHT 2000 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2000, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Apr 19, 2000
Words:300
Previous Article:UroCor Announces Acquisition of Mills Biopharmaceuticals.
Next Article:Pervasive Software Leverages New Macromedia Exchange Site to Deliver Tango Objects for Dreamweaver.



Related Articles
Endovasc Ships First R&D Order of New Therapeutic Stent Coating to Vascular Engineering Inc.
Endovasc Ltd. Inc. Appoints PMR and Associates as New Investor Relations Firm to Assist in Strategic Planning.
Corporate Profile for Endovasc Ltd. Inc., dated July 23, 1999.
ENDV Reports Strong Interest in Company's New Drugs and Market Strategy At the ``Discovery Expo 2000'' in New York.
Endovasc Ltd. Inc. Chairman and CEO Featured on CEOcast.com.
Endovasc Announces Favorable Results for Liprostin and Progresses Into Phase II Clinical Trials.
Endovasc Ltd. Inc. to Participate in Discovery Expo June 14.
ENDOVASC COMMENCES LIPROSTIN TREATMENT FOR NEUROPATHY.
Endovasc's Nutraceutical Development Company Announces Royalty Revenue from Sales of Endothil-CR.
Endovasc Receives Issue Notification for U.S. Patent Protecting its Muscle Mass Technology.

Terms of use | Copyright © 2010 Farlex, Inc. | Feedback | For webmasters | Submit articles